Orris

Create a concise oncology evidence summary on China NMPA conditional approval of savolitinib/ORPATHYS for locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification after failure of at least two prior systemic treatments. Include: approval type, indication, MET amplification testing relevance, pivotal phase 2 study design, ORR, durability/safety findings, and clinical implication for later-line targeted therapy in gastric/GEJ cancer. Keep it practical for oncologists and include citations. Source check: HUTCHMED announced on July 2, 2026 that NMPA granted conditional approval for savolitinib in locally advanced or metastatic MET-amplified GC/GEJ adenocarcinoma after at least two prior systemic therapies; OncLive reported the pivotal phase 2 IRC-assessed ORR as 32.3%.

Searching the Web

savolitinib ORPATHYS NMPA conditional approval gastric cancer MET amplification 2026 HUTCHMED

Searching the Web

savolitinib phase 2 gastric cancer MET amplification ORR 32.3% pivotal study OncLive 2026

Searching PubMed

savolitinib gastric cancer MET amplification

Reading Web Page

https://www.onclive.com/view/savolitinib-gains-nmpa-approval…

Reading Article

PMID: 42225990

Oncology Evidence Summary: Savolitinib (ORPATHYS) for MET-Amplified Gastric/GEJ Adenocarcinoma

July 2026 | For Practicing Oncologists

1. Approval Overview

ParameterDetail
DrugSavolitinib (ORPATHYS) - oral, selective MET TKI
Regulatory authorityChina NMPA
Approval typeConditional approval (NDA)
Approval dateJuly 2, 2026
Developer/CommercializerHUTCHMED + AstraZeneca (joint development); AstraZeneca commercializes in China
Indication numberThird approved indication for savolitinib in China
Full approved indication: Locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma with MET amplification, in patients who have failed at least two prior systemic treatments.
This is the first selective MET inhibitor approved in China for this biomarker-defined population. Savolitinib is already on China's National Reimbursement Drug List (NRDL) from March 2023 for its prior indications, which may facilitate access pathway discussion for this new use.

2. MET Amplification: Prevalence and Testing Relevance

MET amplification occurs in approximately 4-6% of gastric cancers - roughly ~18,000 patients annually in China. It is associated with poor prognosis and, historically, the absence of effective targeted options in the later-line setting.
Why testing matters in practice:
  • The approved indication is tightly biomarker-gated; MET amplification (gene copy number [GCN] ≥10 was required for pivotal phase eligibility) must be confirmed before treatment
  • Low prevalence means routine, quality-assured testing of all GC/GEJ adenocarcinoma patients is essential to identify eligible candidates - ideally at diagnosis or before second-line progression to ensure results are ready if third-line is reached
  • Prior treatment with a MET-targeted agent was an exclusion criterion in the registrational trial; patients with prior MET inhibitor exposure were not studied
  • The VIKTORY Umbrella Trial (Lee et al., Cancer Discovery 2019) earlier demonstrated the prognostic and predictive relevance of MET amplification in metastatic gastric cancer using genomic profiling, supporting biomarker-driven treatment selection

3. Pivotal Phase 2 Study (NCT04923932)

Published: Peng Z, Liu T, Wang H, et al. Nat Med. Published online June 1, 2026. doi:10.1038/s41591-026-04459-7 [PMID: 42225990] Also presented: ASCO Annual Meeting 2026; Peng Z, et al. J Clin Oncol. 2026;44(suppl 16):4011.

Design

FeatureDetails
DesignSingle-arm, open-label, multicenter phase 2 (China)
StructureTwo phases: exploratory (≥1 prior line) + pivotal (≥2 prior lines)
Pivotal phase eligibilityLocally advanced/metastatic GC/GEJ adenocarcinoma; MET amplification GCN ≥10; ≥2 prior systemic therapies including ≥1 fluoropyrimidine- or platinum-based regimen; ECOG PS 0-1; measurable disease per RECIST 1.1
ExclusionPrior MET-targeted therapy
TreatmentSavolitinib 600 mg orally once daily, continuous 21-day cycles until progression, unacceptable toxicity, or consent withdrawal
Primary endpointIRC-assessed ORR per RECIST 1.1 (null hypothesis ORR: 10%; target ORR: 25%)
Secondary endpointsDCR, TTR, DOR, PFS (IRC and investigator); OS (exploratory)
Total enrolled110 patients (45 exploratory + 65 pivotal)
Data cut-offOctober 8, 2025

4. Efficacy Results

Pivotal Phase Population (n = 65)

EndpointResult
IRC-assessed ORR32.3% (95% CI: 21.2%-45.1%)
Pre-specified efficacy thresholdMet (lower 95% CI limit ≥15%)
IRC-assessed DCR63.1% (95% CI: 50.2%-74.7%)
Median time to response (TTR)1.4 months
Median duration of response (DOR)9.7 months (95% CI: 3.7-18.5)
Median PFS4.0 months (95% CI: 2.6-5.0)

Pooled Target Population (n = 85)

EndpointResult
DCR68.2% (95% CI: 57.2%-77.9%)
Median DOR9.2 months (95% CI: 4.2-23.2)
The ORR of 32.3% is clinically meaningful in the third-line GC/GEJ setting, where historical ORRs with cytotoxic or non-biomarker-selected agents typically fall below 15%. The rapid response onset (TTR 1.4 months) is favorable for a heavily pre-treated population with limited time.

5. Durability and Safety

Durability

A median DOR of 9.7 months in the pivotal population (and 9.2 months in the pooled target population) indicates that responses, when achieved, are durable - substantially longer than would be expected from standard salvage chemotherapy in this setting. DOR of up to 23.2 months at the upper bound of the pooled population confidence interval suggests some patients may achieve prolonged benefit.

Safety (All Enrolled, n = 110)

Safety ParameterFinding
Grade ≥3 treatment-related adverse events (TRAEs)34.5% (38/110 patients)
Treatment-related deaths1 (0.9%) overall enrolled; 0 in pivotal phase population
Overall profileManageable; consistent with prior MET inhibitor class experience
The safety profile in the pivotal population (no treatment-related deaths) and the manageable grade ≥3 rate (~35% overall) are reassuring for a later-line monotherapy in patients with advanced GC/GEJ who may have compromised functional status. Specific TRAEs were consistent with known MET inhibitor effects (peripheral edema, nausea, elevated liver enzymes are class-typical findings); no new safety signals were identified.

6. Clinical Implications for Later-Line Targeted Therapy in GC/GEJ

1. A first genuine targeted option in the third-line+ GC/GEJ niche. Until this approval, later-line GC/GEJ cancer had no approved MET-directed option. The only previously approved targeted therapy in third-line+ GC was TAS-102 (trifluridine/tipiracil) or ramucirumab + paclitaxel in second-line. Savolitinib now provides the first biomarker-matched, mechanistically rational option for this subgroup.
2. ORR context and benchmarking. A 32.3% IRC-assessed ORR in third-line+ GC/GEJ compares favorably with non-targeted salvage regimens. The Van Cutsem et al. phase II experience with AMG 337 (another MET inhibitor) in MET-amplified gastroesophageal adenocarcinoma showed ORRs of ~18-31% in small cohorts, suggesting MET amplification is a tractable target in this disease. The MET-targeted therapies systematic review (Dong et al., Mol Diagn Ther 2022, PMID: 35266116) confirmed that MET amplification enriches for clinical benefit from selective MET inhibition.
3. "Conditional" nature of the approval. The conditional approval designation under China's NMPA regulatory framework means HUTCHMED is expected to provide additional confirmatory data - most likely from a randomized controlled trial. Clinicians should anticipate that OS data and randomized comparisons will be required to confirm the magnitude of benefit and to determine whether this translates into a survival advantage. The current pivotal phase 2 is a single-arm, China-only study without a control arm, which limits OS interpretation and cross-trial comparisons.
4. Practical patient selection.
  • Test all GC/GEJ adenocarcinoma patients for MET amplification (NGS or FISH/CISH with GCN threshold) at diagnosis or before second-line progression
  • Eligible candidates: MET GCN ≥10, ECOG PS 0-1, ≥2 prior regimens, no prior MET inhibitor
  • Dose: 600 mg orally once daily
  • Monitor for class-specific TRAEs; manage peripheral edema and hepatotoxicity proactively
5. Scope for future combination strategies. The registrational data support further investigation in randomized trials. Combination with immunotherapy or chemotherapy in earlier lines, or with anti-HER2 agents in co-amplified tumors, may be areas of future development. The phase Ia/Ib study by Wang et al. (Oncologist 2022, PMID: 35445725) established savolitinib's preliminary single-agent activity and biomarker rationale across solid tumors, informing subsequent development.

Key Citations

  1. HUTCHMED Press Release, July 2, 2026. NMPA Approval for ORPATHYS in Gastric Cancer Patients with MET Amplification. HUTCHMED/Globe Newswire
  2. Peng Z, Liu T, Wang H, et al. Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. Published online June 1, 2026. doi:10.1038/s41591-026-04459-7. [PMID: 42225990]
  3. Peng Z, Liu T, Wang J, et al. A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas. J Clin Oncol. 2026;44(suppl 16):4011. doi:10.1200/JCO.2026.44.16_suppl.4011. [2026 ASCO Annual Meeting]
  4. Dong Y, Xu J, Sun B. MET-targeted therapies and clinical outcomes: a systematic literature review. Mol Diagn Ther. 2022 Mar. [PMID: 35266116]
  5. Lee J, Kim ST, Kim K, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov. 2019;9(10):1388-1405. [doi:10.1158/2159-8290.CD-19-044]
  6. OncLive News Report, July 6, 2026. Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma. OncLive
Bottom line for oncologists: Savolitinib 600 mg once daily is now the first approved selective MET inhibitor for MET-amplified advanced GC/GEJ in China, delivering a 32.3% IRC-assessed ORR with a rapid 1.4-month onset and durable responses (median DOR 9.7 months) in a heavily pretreated population. The conditional approval requires confirmatory randomized data. In practice, the key operational step is implementing routine, high-quality MET amplification testing early in the disease course to identify the ~4-6% of patients who stand to benefit.
This is a shared conversation. Sign in to Orris to start your own chat.